AAAAAA

   
Results: 1-22 |
Results: 22
Relative contribution of CYP3A to amitriptyline clearance in humans: In vitro and in vivo studies
Authors: Venkatakrishnan, K Schmider, J Harmatz, JS Ehrenberg, BL von Moltke, LL Graf, JA Mertzanis, P Corbett, KE Rodriguez, MC Shader, RI Greenblatt, DJ
Citation: K. Venkatakrishnan et al., Relative contribution of CYP3A to amitriptyline clearance in humans: In vitro and in vivo studies, J CLIN PHAR, 41(10), 2001, pp. 1043-1054
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors
Authors: von Moltke, LL Greenblatt, DJ Granda, BW Giancarlo, GM Duan, SX Daily, JP Harmatz, JS Shader, RI
Citation: Ll. Von Moltke et al., Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors, J CLIN PHAR, 41(1), 2001, pp. 85-91
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram
Authors: Von Moltke, LL Greenblatt, DJ Giancarlo, GM Granda, BW Harmatz, JS Shader, RI
Citation: Ll. Von Moltke et al., Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram, DRUG META D, 29(8), 2001, pp. 1102-1109
Differential impairment of triazolam and zolpidem clearance by ritonavir
Authors: Greenblatt, DJ von Moltke, LL Harmatz, JS Durol, ALB Daily, JP Graf, JA Mertzanis, P Hoffman, JL Shader, RI
Citation: Dj. Greenblatt et al., Differential impairment of triazolam and zolpidem clearance by ritonavir, J ACQ IMM D, 24(2), 2000, pp. 129-136
Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single doseof alprazolam
Authors: Kaplan, GB Greenblatt, DJ Ehrenberg, BL Goddard, JE Harmatz, JS Shader, RI
Citation: Gb. Kaplan et al., Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single doseof alprazolam, J CL PSYCH, 20(3), 2000, pp. 338-346
Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches
Authors: Venkatakrishnan, K Von Moltke, LL Court, MH Harmatz, JS Crespi, CL Greenblatt, DJ
Citation: K. Venkatakrishnan et al., Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches, DRUG META D, 28(12), 2000, pp. 1493-1504
Kinetics and dynamics of lorazepam during and after continuous intravenousinfusion
Authors: Greenblatt, DJ von Moltke, LL Ehrenberg, BL Harmatz, JS Corbett, KE Wallace, DW Shader, RI
Citation: Dj. Greenblatt et al., Kinetics and dynamics of lorazepam during and after continuous intravenousinfusion, CRIT CARE M, 28(8), 2000, pp. 2750-2757
Comparative kinetics and response to the benzodiazepine agonists triazolamand zolpidem: Evaluation of sex-dependent differences
Authors: Greenblatt, DJ Harmatz, JS von Moltke, LL Wright, CE Durol, ALB Harrel-Joseph, LM Shader, RI
Citation: Dj. Greenblatt et al., Comparative kinetics and response to the benzodiazepine agonists triazolamand zolpidem: Evaluation of sex-dependent differences, J PHARM EXP, 293(2), 2000, pp. 435-443
Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes
Authors: Warrington, JS Poku, JW Von Moltke, LL Shader, RI Harmatz, JS Greenblatt, DJ
Citation: Js. Warrington et al., Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes, J PHARM EXP, 292(3), 2000, pp. 1024-1031
Alprazolam-ritonavir interaction: Implications for product labeling
Authors: Greenblatt, DJ von Moltke, LL Harmatz, JS Durol, ALB Daily, JP Graf, JA Mertzanis, P Hoffman, JL Shader, RI
Citation: Dj. Greenblatt et al., Alprazolam-ritonavir interaction: Implications for product labeling, CLIN PHARM, 67(4), 2000, pp. 335-341
In vitro metabolism of trazodone by CYP3A: Inhibition by ketoconazole and human immunodeficiency viral protease inhibitors
Authors: Zalma, A von Moltke, LL Granda, BW Harmatz, JS Shader, RI Greenblatt, DJ
Citation: A. Zalma et al., In vitro metabolism of trazodone by CYP3A: Inhibition by ketoconazole and human immunodeficiency viral protease inhibitors, BIOL PSYCHI, 47(7), 2000, pp. 655-661
Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions
Authors: von Moltke, LL Greenblatt, DJ Granda, BW Grassi, JM Schmider, J Harmatz, JS Shader, RI
Citation: Ll. Von Moltke et al., Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions, PSYCHOPHAR, 145(1), 1999, pp. 113-122
O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants
Authors: Fogelman, SM Schmider, J Venkatakrishnan, K von Moltke, LL Harmatz, JS Shader, RI Greenblatt, DJ
Citation: Sm. Fogelman et al., O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants, NEUROPSYCH, 20(5), 1999, pp. 480-490
Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: Evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine
Authors: Schmider, J Von Moltke, LL Shader, RI Harmatz, JS Greenblatt, DJ
Citation: J. Schmider et al., Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: Evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine, DRUG METAB, 31(2), 1999, pp. 545-600
Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations
Authors: von Moltke, LL Greenblatt, DJ Granda, BW Duan, SX Grassi, JM Venkatakrishnan, K Harmatz, JS Shader, RI
Citation: Ll. Von Moltke et al., Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations, BR J CL PH, 48(1), 1999, pp. 89-97
Human cytochromes and some newer antidepressants: Kinetics, metabolism, and drug interactions
Authors: Greenblatt, DJ Von Moltke, LL Harmatz, JS Shader, RI
Citation: Dj. Greenblatt et al., Human cytochromes and some newer antidepressants: Kinetics, metabolism, and drug interactions, J CL PSYCH, 19(5), 1999, pp. 23S-35S
Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction
Authors: Greenblatt, DJ von Moltke, LL Daily, JP Harmatz, JS Shader, RI
Citation: Dj. Greenblatt et al., Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction, J CL PSYCH, 19(4), 1999, pp. 293-296
Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder
Authors: Shader, RI Harmatz, JS Oesterheld, JR Parmelee, DX Sallee, FR Greenblatt, DJ
Citation: Ri. Shader et al., Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder, J CLIN PHAR, 39(8), 1999, pp. 775-785
Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects
Authors: von Moltke, LL Greenblatt, DJ Grassi, JM Granda, BW Venkatakrishnan, K Duan, SX Fogelman, SM Harmatz, JS Shader, RI
Citation: Ll. Von Moltke et al., Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects, BIOL PSYCHI, 46(6), 1999, pp. 839-849
Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects
Authors: von Moltke, LL Greenblatt, DJ Grassi, JM Granda, BW Fogelman, SM Harmatz, JS Kramer, SJ Fabre, LF Shader, RI
Citation: Ll. Von Moltke et al., Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects, PSYCHOPHAR, 140(3), 1998, pp. 293-299
Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A
Authors: Von Moltke, LL Greenblatt, DJ Grassi, JM Granda, BW Venkatakrishnan, K Schmider, J Harmatz, JS Shader, RI
Citation: Ll. Von Moltke et al., Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A, J PHARM PHA, 50(9), 1998, pp. 997-1004
Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole
Authors: Greenblatt, DJ von Moltke, LL Harmatz, JS Mertzanis, P Graf, JA Durol, ALB Counihan, M Roth-Schechter, B Shader, RI
Citation: Dj. Greenblatt et al., Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole, CLIN PHARM, 64(6), 1998, pp. 661-671
Risultati: 1-22 |